Skip to main content
< Back to news
Valerie Vanhooren, CEO and co-founder of Ona Therapeutics, Photo / PCB
 09.10.2025

CDTI Innovation leads a €10 million investment in Ona Therapeutics together with five co-investors

The biotechnology company Ona Therapeutics, located in the Barcelona Science Park, has received a €10 million investment, led by SICC Innvierte of CDTI Innovation, to advance the development of new therapies for advanced cancer using ADCs (antibody-drug conjugates). The round also included participation from co-investors Asabys Partners, Ysios Capital Partners, Alta Life Science, the European Venture Capital Fund (FCRE), and Fund+. The funds will be used to develop ADCs and antibody-based therapies, with the goal of providing new treatment options for patients with advanced cancer, who currently have no effective alternatives.

Ona Therapeutics is a pioneer in the development of first-generation antibody-drug conjugates (ADCs) that leverage the molecular foundations of advanced cancer. The company collaborates with academic and medical experts to design therapies that address the complexity of the disease and meet unmet clinical needs. Patients with advanced cancer have often undergone multiple lines of treatment, and their disease progression presents significant challenges due to the limited understanding of how cancer evolves throughout these therapies, making it difficult to identify new therapeutic targets.

This spin-off from the Institute for Research in Biomedicine (IRB Barcelona) applies an innovative approach by incorporating samples from refractory patients, allowing the analysis of how standard treatments transform cancer at the molecular level. Thanks to this knowledge, Ona Therapeutics can identify new therapeutic targets beyond traditional tumour antigens and define patient populations in which these therapies are likely to be most effective.

With this investment, Ona Therapeutics strengthens its strategy for developing ADCs and antibody-based therapies, consolidating its position as a leading company in innovation against advanced cancer.

» Link to the news: CDTI webstite [+]